Seborrheic dermatitis. A modern view of the problem
https://doi.org/10.33667/2078-5631-2025-23-119-126
Abstract
Seborrheic dermatitis is a chronic recurrent inflammatory dermatosis that manifests as erythematous macules or plaques in sebaceous areas. The main components of pathogenesis seborrheic dermatitis: activation of sebaceous glands secretion, Malassezia fungi colonization of the skin, specific immune response. Manifest and recurrences of seborrheic dermatitis depend on individual triggers: impairment of epidermal barrier, genetic factors, neurogenic factors, emotional stress, nutrition, metabolic disorders.
Objective. To identify risk for the development and recurrences of seborrheic dermatitis, to describe the comorbidities, to review the modern methods of treatment of seborrheic dermatitis.
Materials and methods. Article searches were performed in PubMed, Google Scholar, Elibrary over the period from 10 years to 01.02.2025 for the keywords ‘seborrheic dermatitis’, ‘risk factors’, ‘differential diagnosis’, ‘treatment of seborrheic dermatitis’.
Results. The review included 65 publications. Risk factors for the development of seborrheic dermatitis include exogenous (environmental conditions, medications, nutrition) and endogenous factors (male gender, genetics, immune response, comorbidities, psychoemotional stress, metabolic syndrome).
Conclusions. Trigger factors of the development of dermatosis can help to select more effective therapy of seborrheic dermatitis. Research the pathogenesis of seborrheic dermatitis and associated diseases may open new therapeutic targets for the treatment of seborrheic dermatitis.
About the Authors
Yu. N. Perlamutrov
Russian University of Medicin
Russian Federation
Russian Federation
Perlamutrov Yuri N., DM Sci (habil.), professor, head of Dept of Skin and Venereal Diseases
Moscow
D. B. Novikova
Russian University of Medicin
Russian Federation
Russian Federation
Novikova Daria B., postgraduate student at Dept of Skin and Venereal Diseases
Moscow
References
1. Kruglova, L. S., Markelova E. S. Seborrheic dermatitis: issues of effective therapy. Advances in Medical Mycology. 2022; (23): 21–26. (In Russ.).
2. Polonskaya A. S., Shatokhina E. A., Kruglova L. S. Seborrheic dermatitis: current concepts of etiology, pathogenesis, and treatment approaches. Clinical dermatology and venereology. 2020; 19 (4): 451–458. (In Russ.). https://doi.org/10.17116/klinderma20201904145.
3. Jackson J. M., Alexis A., Zirwas M., Taylor S. Unmet needs for patients with seborrheic dermatitis. J Am Acad Dermatol. 2024; 90 (3): 597–604. https://doi: 10.1016/j.jaad.2022.12.017.
4. Adalsteinsson J.A., Kaushik S., Muzumdar S., Guttman Yassky E., Ungar J. An update on the microbiology, immunology and genetics of seborrheic dermatitis. Exp Dermatol. 2020; 29: 481–489. https://doi.org/10.1111/exd.14091.
5. Wikramanayake T.C., Borda L.J., Miteva M., Paus R. Seborrheic dermatitis Looking beyond Malassezia. Exp Dermatol. 2019; 28: 991-1001. https://doi.org/10.1111/exd.14006.
6. Polaskey M. T., Chang C. H., Daftary K., Fakhraie S., Miller C. H., Chovatiya R. The Global Prevalence of Seborrheic Dermatitis: A Systematic Review and Meta Analysis. JAMA Dermatol. 2024; 160 (8): 846–855. https://doi:10.1001/jamadermatol.2024.1987.
7. Tamer F. Relationship between diet and seborrheic dermatitis. Our Dermatol Online. 2018; 9 (3): 261–264.
8. Tucker D., Masood S. Seborrheic Dermatitis. Seborrheic Dermatitis. In: StatPearls [Internet]. 2024. https://www.ncbi.nlm.nih.gov/books/NBK551707.
9. Sanders, M. Seborrheic Dermatitis: More than meets the eye. Doctoral Thesis, Erasmus University Rotterdam. 2021. http://hdl.handle.net/1765/135626.
10. Zander N., Sommer R., Schafer I et al. Epidemiology and dermatological comorbidity of seborrhoeic dermatitis: population based study in 161269 employees. Br J Dermatol. 2019; 181: 743–748.
11. Sanders M.G.H., Pardo L.M., Franco O.H. et al. Prevalence and determinants of seborrhoeic dermatitis in a middle aged and elderly population: the Rotterdam Study. Br J Dermatol. 2018; 178 (1): 148–153.
12. Alexis A.F., Sergay A.B., Taylor S.C. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007; 80 (5): 387–394.
13. Sanders M.G.H., Pardo L.M., Ginger R.S., Kiefte de Jong J.C., Nijsten T. Association between diet and seborrheic dermatitis: a cross sectional study. J Invest Dermatol. 2019; 139 (1): 108–114.
14. Tomic S., Kuric I., Kuric T.G., Popovic Z., Kragujevic J., Zubonja T.M., Rajkovaca I., Matosa S. Seborrheic Dermatitis Is Related to Motor Symptoms in Parkinson’s Disease. J Clin Neurol. 2022; 18 (6): 628–634. https://doi:10.3988/jcn.2022.18.6.628.
15. Karakadze M.A., Hirt P.A., Wikramanayake T.C. The genetic basis of seborrheic dermatitis: a review. J Eur Acad Dermatol Venereol. 2018 Apr; 32 (4): 529–536. https://doi:10.1111/jdv.14704.
16. Mirnezami M., Zarinfar N., Sofian M., Botlani Yadegar B., Rahimi H. Mucocutaneous manifestations in HIV-infected patients and their relationship to CD4 lymphocyte counts. Scientifica (Cairo). 2020; 2020:750–756.
17. Laurence M., Benito León J., Calon F. Malassezia and Parkinson’s Disease. Front Neurol. 2019; 10: 758. https://doi: 10.3389/fneur.2019.00758.
18. Langan E.A., Hinde E., Paus R. Prolactin as a candidate sebotrophic hormone? Exp Dermatol. 2018;27(7):729–736. https://doi:10.1111/exd.13545.
19. De Avelar Breunig J., Couto M.O.R. Seborrheic Dermatitis. Dermatology in Public Health Environments. 2017; 429–447. https://doi.org/10.1007/978-3-319-33919-1_20.
20. Misery L., Touboul S., Vinсot C., Dutray S., Rolland Jacob G., Consoli S.G., Farcet Y., Feton Danou N., Cardinaud F., Callot V., De La Chapelle C., Pomey Rey D., Consoli S.M. Stress and seborrheic dermatitis. Ann Dermatol Venereol. 2007; 134 (11): 833–837. https://doi:10.1016/s0151–9638(07)92826-4.
21. Etgu F. Analysis of the epidemiology, coexisting skin diseases, and variables affecting seborrheic dermatitis severity. Med Science. 2023; 12 (4): 994–997.
22. Sarac E., Kocatürk E. Relationship between disease severity, perceived stress, and depression in patients with seborrheic dermatitis. Marmara Med J. 2022; 35 (3): 362–366. https://doi:10.5472/marumj.1195298.
23. Pondeljak N., Lugović Mihić L. Stress induced interaction of skin immune cells, hormones, and neurotransmitters. Clin Ther. 2020; 42: 757–770. https://doi:10.1016/j.clinthera.2020.03.008.
24. Castillo D.E., Gunczler I., Franсa, K., Keri J. Seborrheic Dermatitis. Advances in Integrative Dermatology. 2019; 71–88. https://doi.org/10.1002/9781119476009.ch6
25. Sparber F., De Gregorio C., Steckholzer S. et al. The skin commensal yeast Malassezia triggers a type 17 response that coordinates anti fungal immunity and exacerbates skin inflammation. Cell Host Microbe. 2019; 25:389–403.
26. Park M., Cho Y.J., Kim D. et al. A novel virus alters gene expression and vacuolar morphology in Malassezia cells and induces a TLR3 mediated inflammatory immune response. mBio. 2020; 11 (5): e01521–20.
27. Woolhiser E., Keime N., Patel A., Weber I., Adelman M., Dellavalle R.P. Nutrition, Obesity, and Seborrheic Dermatitis: Systematic Review JMIR Dermatol 2024; 7: e50143. URL: https://derma.jmir.org/2024/1/e50143. https://doi:10.2196/50143.
28. Graubard R., Perez Sanchez A., Katta R. Stress and skin: an overview of mind body therapies as a treatment strategy in dermatology. Dermatol Pract Concept. 2021; 11 (4): e2021091. https://doi.org/10.5826/dpc.1104a91.
29. Dall’Oglio F., Nasca M.R., Gerbino C., Micali G. An Overview of the Diagnosis and Management of Seborrheic Dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2022; (15): 1537–1548. https://doi.org/10.2147/CCID.S284671.
30. Kang S., Amagai M., Bruckner A., Enk A., Margolis D.J., Mcmichael A.J., Orringer JS. Fitzpatrick’s Dermatology, 9th ed. New York: McGraw Hill. 2019; 428.
31. Aslan K.M., Wang J.V, Karadag A.S. Papulosquamous annular diseases. Clin Dermatol. 2022; 40 (5): 441–449. https://doi:10.1016/j.clindermatol.2021.12.007.
32. Clark G.W., Pope S.M., Jaboori K.A. Diagnosis and treatment of seborrheic dermatitis. Am Fam Physician. 2015; 91 (3): 185–190.
33. Limbu S.L., Purba T.S., Harries M., Wikramanayake T.C., Miteva M., Bhogal R.K., O’Neill C. A., Paus R. A Folliculocentric Perspective of Dandruff Pathogenesis: Could A Troublesome Condition Be Caused by Changes to a Natural Secretory Mechanism? BioEssays. 2021; e2100005. https://doi.org/10.1002/bies.202100005
34. Lacarrubba F. Clinical and trichoscopic aspects of scalp psoriasis: commentary to ‘Clinical and trichoscopic features in various forms of scalp psoriasis’ by F. Bruni et al. J Eur Acad Dermatol Venereol. 2021; 35 (9): 1744–1745.
35. Klosowicz A., Alsalhi W., Tosti A. How to Optimize Trichoscopy for Evaluation of Scalp Vessels. Skin Appendage Disord. 2020; 6 (4): 216–219. https://doi: 10.1159/000508166.
36. Golinska J., Sar Pomian M., Rudnicka L. Diagnostic Accuracy of Trichoscopy in Inflammatory Scalp Diseases: A Systematic Review. Dermatology. 2022; 238 (3): 412–421. https://doi:10.1159/000517516.
37. Xu C., Chen D., Liu J., Liu Y., Sun Q. Roles of dermoscopy in the diagnosis and differential diagnosis of scalp psoriasis and seborrheic dermatitis. Zhonghua Yi Xue Za Zhi. 2014; 94 (44): 3467–3470.
38. Yu Z., Kaizhi S., Jianwen H., Guanyu Y., Yonggang W. A deep learning based approach toward differentiating scalp psoriasis and seborrheic dermatitis from dermoscopic images. Front. Med. 2022; (9): 965423. https://doi:10.3389/fmed.2022.965423/
39. Alpalhao M., Gaibino N., Filipe P. Seborrheic dermatitis in COVID 19: a case report. Int J Dermatol. 2020;59(12):1543–1544. https://doi:10.1111/ijd.15256.
40. Leroy A.K., Cortez de Almeida R.F., Obadia D.L., Frattini S., Melo D.F. Scalp Seborrheic Dermatitis: What We Know So Far. Skin Appendage Disord. 2023; 9 (3): 160–164. https://doi:10.1159/000529854/
41. Khryanin A. A., Russkikh M. V., Bocharova V. K., Nadeev A. P. Seborrheic dermatitis associated with HIV infection: new concepts and hypotheses. HIV Infection and Immunosuppression. 2020; 12 (4): 98–107. (In Russ.). http://dx.doi.org/10.22328/2077-9828-2020-12-4-98-107
42. Ozgul A., Altunisik N., Turkmen D., Sener S. The relationship between seborrheic dermatitis and body composition parameters. North Clin Istanb. 2023; 10 (2): 271–276.
43. Massiot P., Clavaud C., Thomas M., Ott A., Gueniche A., Panhard S., Muller B., Michelin C., Kerob D., Bouloc A., Reygagne P. Continuous clinical improvement of mild-to-moderate seborrheic dermatitis and rebalancing of the scalp microbiome using a selenium disulfide based shampoo after an initial treatment with ketoconazole. J Cosmet Dermatol. 2022; 21 (5): 2215–2225. http://doi:10.1111/jocd.14362.
44. Vano Galvan S., Reygagne P., Melo D.F., Barbosa V., W Wu, Moneib H., Piraccini B.M. A comprehensive literature review and an international expert consensus on the management of scalp seborrheic dermatitis in adults. Eur J Dermatol. 2024; 34 (S1): 4–16. http://doi:10.1684/ejd.2024.4703.
45. Desai S., McCormick E., Friedman A. An Up to Date Approach to the Management of Seborrheic Dermatitis. J Drugs Dermatol. 2022; 21 (12): 1373–1374. http://doi:10.36849/JDD.1022.
46. Patel R.T., Gay J.J., Fagan K.K., Eikenberg J.D. Non psoriatic uses of calcipotriol: a concise updated review. Dermatol Online J. 2023; 29 (3): 10.5070/D329361422. http://doi:10.5070/D329361422.
47. Alsmeirat O., Lakhani S., Egaimi M. et al. The Efficacy and Safety of Pimecrolimus in Patients With Facial Seborrheic Dermatitis: A Systematic Review of Randomized Controlled Trials. Cureus. 2022; 14 (8): e27622. http://doi:10.7759/cureus.27622.
48. Borda L.J., Perper M., Keri J.E. Treatment of seborrheic dermatitis: a comprehensive review. Journal of Dermatological Treatment. 2018; 30 (2): 158–169. https://doi.org/10.1080/09546634.2018.1473554.
49. Kim H.O., Yang Y.S., Ko H.C., Kim G.M., Cho S.H., Seo Y.J., Son S.W., Lee J.R., Lee J.S., Chang S.E., Che J.W., Park C.W. Maintenance therapy of facial seborrheic dermatitis with 0.1% tacrolimus ointment. Ann Dermatol. 2015; 27 (5): 523–530.
50. Al Janabi A., Marsland A.M. Seborrhoeic dermatitis and sebopsoriasis developing in patients on dupilumab: Two case reports. Clin Case Rep. 2020; 8(8): 1458–1460.
51. Yanfei Z., Xiaoying N., Dingwei Z., Wei W., Jianwen R. Efficacy and safety of oral isotretinoin in the treatment of moderate to severe seborrheic dermatitis: a retrospective study. Int J Dermatol. 2023; 62(6):759–763.
52. Gualtieri B., Panduri S., Chiricozzi A., Romanelli M. Improvement of severe facial seborrheic dermatitis following low dose isotretinoin therapy. G Ital Dermatol Venereol. 2020; 155 (5): 685–686. http://doi:10.23736/S0392–0488.18.06029–7.
53. de Souza Leão Kamamoto C., Sanudo A., Hassun K., Bagatin E. Low dose oral isotretinoin for moderate to severe seborrhea and seborrheic dermatitis: a randomized comparative trial. Int J Dermatol. 2017; 56 (1): 80–85. http://doi:10.1111/ijd.13408.
54. Bagatin E., Costa C.S., Rocha M.A.D.D. et al. Consensus on the use of oral isotretinoin in dermatology – Brazilian Society of Dermatology. An Bras Dermatol. 2020; 95 (1): 19–38. http://doi:10.1016/j.abd.2020.09.001.
55. King A., Tan M.G., Kirshen C., Tolkachjov S.N. Isotretinoin for the management of moderate to severe seborrheic dermatitis: A systematic review. J Am Acad Dermatol. 2023;89(5):1063–1066. http://doi:10.1016/j.jaad.2023.07.010.
56. Sobhan M., Gholampoor G., Firozian F., Mohammadi Y., Mehrpooya M. Comparison of efficacy and safety of atorvastatin 5% lotion and betamethasone 0.1% lotion in the treatment of scalp seborrheic dermatitis. Clin Cosmet Investig Dermatol. 2019; 29 (12): 267–275.
57. Vincenzi C., Tosti A. Efficacy and tolerability of a shampoo containing broad spectrum Cannabidiol in the treatment of scalp inflammation in patients with mild to moderate scalp psoriasis or seborrheic dermatitis. Skin Appendage Disord. 2020; 6 (6): 355–361.
58. Brian Park P. Roflumilast foam looks promising in seborrheic dermatitis Trial. Medical Professionals Reference. 2022.
59. Zirwas M. J., Draelos Z. D., DuBois J. et al. Efficacy of Roflumilast Foam, 0.3 %, in Patients With Seborrheic Dermatitis: A Double blind, Vehicle Controlled Phase 2a Randomized Clinical Trial. JAMA Dermatol. 2023; 159 (6): 613–620. http://doi:10.1001/jamadermatol.2023.0846.
60. Chovatiya R., Polaskey M.T., Lain E. et al. Putting the Formulation Back in Foam: Optimizing Seborrheic Dermatitis Treatment Across Diverse Hair Types. J Clin Aesthet Dermatol. 2024; 17 (5): 30–33.
61. Liu D., Chow P., Strawn S., Rajpara A., Wang T., Aires D. Chronic nasolabial fold seborrheic dermatitis successfully controlled with Crisaborole. J Drugs Dermatol. 2018; 17 (5): 577–578.
62. Mital R., Gray A., Minta A. et al. Novel and Off Label Biologic Use in the Management of Hidradenitis Suppurativa, Pyoderma Gangrenosum, Lichen Planus, and Seborrheic Dermatitis: A Narrative Review. Dermatol Ther (Heidelb). 2023; 13 (1): 77–94. http://doi:10.1007/s13555-022-00860-5.
63. Lukac D., Pagani K., McGee J.S. Overview of use, efficacy, and safety of dupilumab in complex patients: a retrospective, case series study from a large, urban academic center. Arch Dermatol Res. 2022. https://doi.org/10.1007/s00403–022–02362-y.
64. Papp K., Szepietowski J.C., Kircik L. et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double blind studies. J Am Acad Dermatol. 2021; 85 (4): 863–872. https://doi.org/10.1016/j.jaad.2021.04.085.
65. Pope E., Kowalski E., Tausk F. Topical ruxolitinib in the treatment of refractory facial seborrheic dermatitis. JAAD case reports. 2022; 24: 59–60. https://doi.org/10.1016/j.jdcr.2022.04.003.
Review
For citations:
Perlamutrov Yu.N., Novikova D.B. Seborrheic dermatitis. A modern view of the problem. Medical alphabet. 2025;1(23):119-126. (In Russ.) https://doi.org/10.33667/2078-5631-2025-23-119-126
Views:
9
Email this article 